LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・Sanofi

Sanofi

Затворен

57.74 -0.89

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

57.56

Максимум

58.67

Ключови измерители
By Trading Economics
Приходи	-20M 1.1B
Продажби	262M 11B
P/E Средно за сектора	25.1 103.001
EPS	0.455
Марж на печалбата	9.78
EBITDA	-136M 2B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	-0.41 downside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	142B
Предишно отваряне	58.63
Предишно затваряне	57.74

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

56.21 / 58.15 Подкрепа & съпротива

Sanofi Графика

Свързани новини

25.07.2024 г., 05:44 ч. UTC

Печалби

Sanofi Raises Guidance After Profit, Sales Beat

4.07.2024 г., 06:44 ч. UTC

Придобивния, сливания и поглъщания

Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports

27.06.2024 г., 10:54 ч. UTC

Значими двигатели на пазара

Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment

26.06.2024 г., 07:15 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Starts Bidding Process to Sell Consumer Health Division, Bloomberg Reports

13.05.2024 г., 18:14 ч. UTC

Значими двигатели на пазара

Novavax Shares Pop Another 50% Following Sanofi Deal

25.07.2024 г., 13:20 ч. UTC

Печалби

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

25.07.2024 г., 11:46 ч. UTC

Пазарно говорене

Печалби

Sanofi Aims to Boost RSV Drug Supply -- Market Talk

25.07.2024 г., 11:23 ч. UTC

Пазарно говорене

Печалби

Sanofi Results Are Positive -- Market Talk

25.07.2024 г., 05:33 ч. UTC

Печалби

Analysts Saw Sanofi 2Q Sales at EUR10.4B

25.07.2024 г., 05:33 ч. UTC

Печалби

Sanofi 2Q Sales EUR10.745B

25.07.2024 г., 05:30 ч. UTC

Печалби

Sanofi Had Seen 2024 Business Earnings Per Share Decreasing Low Single Digit at Constant Currency

25.07.2024 г., 05:30 ч. UTC

Печалби

Sanofi Now Expects 2024 Business Earnings Per Share to Be Stable at Constant Currency

25.07.2024 г., 05:30 ч. UTC

Печалби

Analysts Saw Sanofi 2Q Business Operating Income at EUR2.69B

25.07.2024 г., 05:30 ч. UTC

Печалби

Sanofi 2Q Net Pft EUR1.11B

25.07.2024 г., 05:30 ч. UTC

Печалби

Sanofi Raises 2024 View

25.07.2024 г., 05:30 ч. UTC

Печалби

Sanofi 2Q Business Operating Income EUR2.81B

9.07.2024 г., 09:05 ч. UTC

Топ новини

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

3.07.2024 г., 14:18 ч. UTC

Придобивния, сливания и поглъщания

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

27.06.2024 г., 10:39 ч. UTC

Значими двигатели на пазара

Vigil Neuroscience Shares Soar on $40M Sanofi Investment

27.06.2024 г., 06:08 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience Is a Clinical-Stage Biotechnology Company >VIGL

27.06.2024 г., 06:08 ч. UTC

Придобивния, сливания и поглъщания

Vigil: Program Includes Clinical Candidate VG-3927, Being Evaluated in Phase 1 Study for Alzheimer's >VIGL

27.06.2024 г., 06:08 ч. UTC

Придобивния, сливания и поглъщания

Vigil: To Grant Sanofi Exclusive Right of First Negotiation for License of Small Molecule TREM2 Agonist Program >VIGL

27.06.2024 г., 06:07 ч. UTC

Придобивния, сливания и поглъщания

Vigil Expects Proceeds to Extend Cash Runway Into 2026 >VIGL

27.06.2024 г., 06:06 ч. UTC

Придобивния, сливания и поглъщания

Vigil: Will Use Proceeds to Fund R&D Activities >VIGL

27.06.2024 г., 06:06 ч. UTC

Придобивния, сливания и поглъщания

Vigil: Each Share Convertible Into 10 Shares of Common Stock >VIGL

27.06.2024 г., 06:06 ч. UTC

Придобивния, сливания и поглъщания

Vigil: Sanofi Will Purchase 537,634 of Company's Series A Non-Voting Preferred Shares >VIGL

30.05.2024 г., 13:10 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Acquisition Relates to Human Protein to Treat Patients With Rare Hereditary Diseases

30.05.2024 г., 13:08 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Completes Acquisition of Biotech Inhibrx

30.05.2024 г., 13:01 ч. UTC

Придобивния, сливания и поглъщания

Press Release: Sanofi Completes Acquisition Of Inhibrx, Inc. >SAN.FR

10.05.2024 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Inhibrx: Following Inhibrx Merger With Sanofi, Inhibrx Biosciences to Trade Under INBX

Сравнение с други в отрасъла

Ценова промяна

Sanofi Прогноза

Ценова цел

By TipRanks

-0.41% надолу

12-месечна прогноза

Среден 58 USD -0.41%

Висок 60 USD

Нисък 56 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Sanofi през последните 3 месеца.

Техническа оценка

By Trading Central

56.21 / 58.15Подкрепа & съпротива

The bullish and bearish events are balanced.

All events are bullish.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Sanofi

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.